1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
681A36793B0EA20B900258A30003F87A6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-rare-blood-disorders-msl-team-excellence-benchmarking-roles-staffing-levels?opendocument
18
19opendocument
203.92.91.54
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Field Medical Excellence

Rare Blood Disorders MSL Team Excellence: Benchmarking Roles and Staffing Levels

ID: 5779


Features:

10 Info Graphics

8 Data Graphics

80+ Metrics

7 Narratives


Pages/Slides: 23


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Rare Blood Disorders MSL Team Excellence: Benchmarking Roles and Staffing Levels”

STUDY OVERVIEW

In a dynamic era of evolving responsibilities, field medical teams in the realm of Rare Blood Disorders are undergoing a profound transformation that demands innovative structural approaches and strategic stakeholder support.

Best Practices, LLC undertook benchmarking research to unveil the current and emerging trends in managing field-based, hybrid, and virtual MSLs in the Rare Blood Disorders therapeutic area. This study serves as a guide for Rare Blood Disorders field medical leaders as they navigate the intricacies of ensuring the right talent is in place and optimizing staffing levels and team structures to maximize their impact.

KEY TOPICS

  • Rare Blood Disorders Staffing Levels: Traditional MSLs vs. Hybrid MSLs
  • Drivers of Rare Blood Disorders Field Team Evolution
  • Medical vs. Commercial Field Resourcing

KEY METRICS

  • How many MSLs and senior MSLs of each type (Traditional MSLs vs. Hybrid MSLs vs. Virtual MSLs) are currently staffed to the Rare Blood Disorders field team?
  • Average number of Rare Blood MSLs; MSL-to-senior MSL ratio at benchmark Rare Blood Disorders organizations
  • How effective are each of the listed MSL job roles in Rare Blood Disorders segment?
  • How critical have each of the listed factors been in shaping the current size and composition of roles within the Rare Blood Disorders field team?
  • Predicted changes in rare blood disorders MSL staffing levels over the next 12-24 months
  • How many staff (FTEs) are currently allocated to the listed Rare Blood Disorders field team roles?

SAMPLE KEY FINDINGS

  • Assessing MSL effectiveness by type: Field-based and hybrid MSLs are deemed similarly effective by benchmark organizations, with approximately 80% calling them “highly effective” or “somewhat effective” in their niche. In terms of future investment, 38% of field leaders predict slight-to-moderate growth in field-based MSL staffing levels over the next 2 years, while another only 42% predict similar growth in hybrid staffing levels.

METHODOLOGY

Best Practices, LLC engaged Field Medical and other Medical Affairs leaders from 17 top Rare Blood Disorders manufacturers in this research through a benchmark survey. Deep-dive interviews were also conducted with field medical leaders to capture additional insights.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Agios; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Astellas; Bayer; BioMarin; Chiesi; CSL Behring; Fresenius Medical Care; Kyowa Kirin; Legend Biotech; Novartis; Novo Nordisk; Servier; Sobi; Takeda Pharmaceuticals; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.